Skip to main content

Advertisement

SpringerLink
Log in

Managing IBD Therapies in Pregnancy

  • Inflammatory Bowel Disease (G Lichtenstein, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Inflammatory bowel disease is frequently diagnosed before or during key childbearing years. One of the most important factors for a healthy pregnancy is having quiescent disease prior to conception and maintaining disease remission for the duration of the pregnancy. In order to achieve that, most women will need to continue their inflammatory bowel disease (IBD) treatment during pregnancy. One of the main concerns these women have is whether these medications will have adverse effects on their growing fetus. Aminosalicylates, antibiotics, and steroids are all relatively low risk for use during pregnancy and breastfeeding. Recent studies also support the safety of continuing immunomodulators and anti-tumor necrosis factor agents during pregnancy and with breastfeeding. There seems to be an increased risk for infection, however, with use of combination therapy including both a biologic agent and an immunomodulator. Less evidence is available on the use of anti-integrins in pregnancy; however, the current data suggest they may be safe as well. Conversations about a patient’s desire for pregnancy should occur between the patient and provider on a regular basis prior to conception and particularly with any change in disease activity or change in the treatment regimen. This chapter will review the current evidence on the safety of IBD medications during pregnancy and lactation so that providers can more easily discuss the importance of medication adherence for disease remission with their patients who are contemplating conception.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.

    Article  PubMed  Google Scholar 

  2. Andres PG, Friedman LS. Epidemiology and natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28(2):255–81.

    Article  CAS  PubMed  Google Scholar 

  3. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut. 1984;25:52–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. •• Ording Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease and after surgery compared to a population sample. Gastroenterology. 2002;122(1):15–9. Large population-based study showing the decrease in fecundity after ileal pouch anal anastomosis creation.

    Article  PubMed  Google Scholar 

  5. Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55:1575–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. •• Getahun D, Fassett M, Longstreth G, et al. Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014;34:435–40. Large population-based study showing that inflammatory bowel disease increases the risk for adverse pregnancy outcomes.

    Article  CAS  PubMed  Google Scholar 

  7. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56(6):830–7.

    Article  CAS  PubMed  Google Scholar 

  8. Ban L, Tata L, Fiaschi L, et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 2014;146:76–84.

    Article  CAS  PubMed  Google Scholar 

  9. Bröms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091–8.

    PubMed  Google Scholar 

  10. Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15(5):720–5.

    Article  PubMed  Google Scholar 

  11. Zelinkova Z, Mensink P, Dees J, et al. Reproductive wish represents an important factor in influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol. 2010;45:46–50.

    Article  PubMed  Google Scholar 

  12. de Lima A, Zelinkova A, Mulders A, et al. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol. 2016;14:1285–91.

    Article  PubMed  Google Scholar 

  13. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling [Federal Register Web site]. Available at: http://federalregister.gov/a/2014-28241. 2014. Accessed July 20 2016.

  14. Diav-Citrin O, Park Y, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective contolled cohort study. Gastroenterology. 1998;144:23–8.

    Article  Google Scholar 

  15. Nørgård B, Fonager K, Pedersen L, et al. Birth outcome in women exposed to 5-aminosalycylic acid during pregnancy: a Danish cohort study. Gut. 2003;52:243–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Marteau P, Tennenbaum R, Elefant E, et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalamine microgranules. Aliment Pharmacol Ther. 1998;12:1101–8.

    Article  CAS  PubMed  Google Scholar 

  17. Rahimi R, Nikfar S, Rezale A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25:271–5.

    Article  CAS  PubMed  Google Scholar 

  18. Nguyen GC, Seow C, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734–57.

    Article  PubMed  Google Scholar 

  19. Caro-Paton T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44:179–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol. 1998;105(3):322–7.

    Article  CAS  PubMed  Google Scholar 

  21. Diav-Citrin O, Shechtman S, Gotteiner T, et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology. 2001;63:186–92.

    Article  CAS  PubMed  Google Scholar 

  22. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998;42:1336–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Larsen H, Nielsen GL, Schonheyder HC, et al. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents. 2001;18:259–62.

    Article  CAS  PubMed  Google Scholar 

  24. Bar-Oz B, Moretti M, Boskovic R, et al. The safety of quinolones - A meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143:75–8.

    Article  CAS  PubMed  Google Scholar 

  25. Park-Wylie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92.

    Article  Google Scholar 

  26. Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol. 2003;67(12):968–70.

    Article  CAS  PubMed  Google Scholar 

  27. Nielsen OH, Andreasson B, Bondersen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol. 1983;18(6):735–42.

    Article  CAS  PubMed  Google Scholar 

  28. Nielsen OH, Andreasson B, Bondersen S, et al. Pregnancy in Crohn's disease. Scand J Gastroenterol. 1984;19(6):724–32.

    CAS  PubMed  Google Scholar 

  29. Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med. 1986;79(4):221–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Molnár T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol. 2010;45:1302–6.

    Article  PubMed  Google Scholar 

  31. Lin K, Martin CF, Dassopoulos T, et al. Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: Results of the PIANO registry. Gastroenterology. 2015;146:S1.

    Article  Google Scholar 

  32. Reddy D, Murphy SJ, Kane SV, et al. Relapses in inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–9.

    Article  CAS  PubMed  Google Scholar 

  33. Beaulieu DB, Ananthakrishnan A, Issa M, et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis. 2009;15(1):25–8.

    Article  PubMed  Google Scholar 

  34. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240–61.

    Article  CAS  PubMed  Google Scholar 

  35. Nørgård B, Pedersen L, Fonager K, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther. 2003;17:827–34.

    Article  PubMed  Google Scholar 

  36. •• Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60:198–203. Recent large cohort study that demonstrated no increased risk of adverse pregnancy outcomes or congenital anomalies.

    Article  PubMed  Google Scholar 

  37. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.

    Article  CAS  PubMed  Google Scholar 

  38. Akbari M, Shah S, Velayos FS, et al. Systemic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15–22.

    Article  PubMed  Google Scholar 

  39. Mahadevan U, Martin C, Sandler RS, et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142:S149.

    Article  Google Scholar 

  40. Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-a drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433–40.

    Article  CAS  PubMed  Google Scholar 

  41. De Meij TGJ, Jharap B, Kneepkens CMF, et al. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:38–43.

    Article  CAS  PubMed  Google Scholar 

  42. Bar-Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71:1051–5.

    Article  CAS  PubMed  Google Scholar 

  43. Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut. 2005;54:1822–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Westbrook RH, Yeoman A, Agarwal K, et al. Outcomes of pregnancy following liver transplantation: The King's College Hospital experience. Liver Transpl. 2015;21(9):1153–9.

    Article  PubMed  Google Scholar 

  45. Nevers W, Pupco A, Koren G, Bozzo P. Safety of tacrolimus in pregnancy. Can Fam Physician. 2014;60:905–6.

    PubMed  PubMed Central  Google Scholar 

  46. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385–92.

    Article  PubMed  Google Scholar 

  47. Lichtenstein GR, Feagen B, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Jurgens M, Brand S, Filik L, et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis. 2010;16:1634–6.

    Article  PubMed  Google Scholar 

  49. McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during and after pregnancy. Inflamm Bowel Dis. 2016;22(1):213–31.

    Article  PubMed  Google Scholar 

  50. Mahadevan U, Vermeire S, Wolf DC, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from safety surveillance [abstract]. Gastroenterology. 2015;148(4 Suppl 1):S858–9.

    Article  Google Scholar 

  51. Vasiliauskas EA, Church J, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255–8.

    Article  PubMed  Google Scholar 

  52. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–92.

    Article  CAS  PubMed  Google Scholar 

  53. Zelinkova A, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318–21.

    Article  CAS  PubMed  Google Scholar 

  54. de Lima A, Zelinkova A, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65(8):1261–8.

    Article  PubMed  Google Scholar 

  55. •• Julsgaard M, Christensen L, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110–9. Large, recent study showing an increased risk of infection in infants exposed to combination therapy and showed detectable anti-TNF drug levels in the infants up to 12 months of age.

    Article  CAS  PubMed  Google Scholar 

  56. Julsgaard M, Brown S, Gibsone P, Bell S. Adalimumab levels in an infant. J Crohns Colitis. 2013;7:597–8.

    Article  PubMed  Google Scholar 

  57. Mahadevan U, Martin CF, Dubinsky M, et al. Exposure to anti-TNFα therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry. Gastroenterology. 2014;146:S170.

    Article  Google Scholar 

  58. •• Zelinkova A, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053–8. This study showed that infliximab drug levels were still detectable in cord blood despite discontinuing treatment prior to 30 weeks gestation, providing important information for management and counseling of patients.

    Article  CAS  PubMed  Google Scholar 

  59. Sheibani S, Cohen R, Kane S, et al. The effect of maternal peripartum anti-TNFα use on infant immune response. Dig Dis Sci. 2016;61:1622–7.

    Article  CAS  PubMed  Google Scholar 

  60. Mahadevan U, Martin CF, Chambers C, et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: The PIANO Registry. Gastroenterology. 2014;146:S-1.

    Article  Google Scholar 

  61. van der Woude CJ, Kolacek S, Dotan I, et al. European evidence-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010;4:493–510.

    Article  PubMed  Google Scholar 

  62. Bossuyt P, Vermeire S. Treat to target in inflammatory bowel disease. Curr Treat Options Gastro. 2016;14:61–72.

    Article  Google Scholar 

  63. Van Assche G, Madelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenteorlogy. 2008;134:1861–8.

    Article  CAS  Google Scholar 

  64. Torres J, Boyapati RK, Kennedy NA, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149:1716–30.

    Article  CAS  PubMed  Google Scholar 

  65. Haghikia A, Langer-Gould A, Reliensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–5.

    Article  PubMed  Google Scholar 

  66. Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205.

    Article  CAS  PubMed  Google Scholar 

  67. Bayas A, Penzien J, Helwigg K. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis. Acta Neurol Scand. 2011;124:290–2.

    Article  CAS  PubMed  Google Scholar 

  68. Hoevenaren IA, de Vries LC, Rijnders RJP, Lotgering FK. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand. 2011;123:430–3.

    Article  CAS  PubMed  Google Scholar 

  69. Theaudin M, Elefant E, Senat MV. Natalizumab continuation during pregnancy in a patient with previous severe IRIS syndrome. J Neur Sci. 2015;359:211–2.

    Article  CAS  Google Scholar 

  70. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63.

    Article  PubMed  Google Scholar 

  71. Mahadevan U, Nazareth M, Cristiano L, et al. Natalizumab use in pregnancy. Am J Gastroenterol. 2008;103:s449.

    Google Scholar 

  72. Dubinsky M, Mahadevan U, Vermeire S, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. ECCO. 2015;P563

  73. Data on file. Reports of pregnancy with ustekinumab: STE/Inj/DoF/Sep2010/EMEA001. 2010, Janssen.

  74. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012;6(4):105–7.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Rocha K, Piccinin MC, Kalache L, et al. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology. 2015;231:103–4.

    Article  PubMed  Google Scholar 

  76. Adrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11(10):1240–1.

    Google Scholar 

  77. Alsenaid A, Prinz JC. Inadvertant pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. JEADV. 2016;30:488–90.

    CAS  PubMed  Google Scholar 

  78. Sheeran C, Nicolopoulos J. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol. 2014;55:235–6.

    Article  PubMed  Google Scholar 

  79. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirhumatic drugs before pregnancy, during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.

    Article  PubMed  Google Scholar 

  80. Christensen LA, Rasmussan SN, Hansen SH, et al. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid. Acta Obstet Gynecol Scand. 1987;66:433–5.

    Article  Google Scholar 

  81. Khan AK, Truelove SC. Placental and mammary transfer of sulfasalazine. Br Med J. 1979;2:1553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhea - a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr. 1986;5:316–7.

    Article  CAS  PubMed  Google Scholar 

  83. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;1:383.

    Article  CAS  PubMed  Google Scholar 

  84. Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options ofr psoriasis in pregnant or lactacting women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:459–77.

    Article  PubMed  Google Scholar 

  85. Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985;106:1008–11.

    Article  CAS  PubMed  Google Scholar 

  86. Niebyl JR. Antibiotics and other anti-infective agents pregnancy and lactation. Am J Perinatol. 2003;20:405–14.

    Article  PubMed  Google Scholar 

  87. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011;96:874–80.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol. 2006;62:453–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Angelberger S, Reinisch W, Messerschmidt A, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011;5:95–100.

    Article  PubMed  Google Scholar 

  90. Ben-Horin S, Yovzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555–8.

    Article  PubMed  Google Scholar 

  91. Ben-Horin S, Yovzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475–6.

    Article  PubMed  Google Scholar 

  92. Martin PL, Oneda S, Treacy G. Effects of an anti-TNFa monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol. 2007;58:138–49.

    Article  CAS  PubMed  Google Scholar 

  93. Natalizumab (Tysabri) package insert. Cambridge: Biogen Inc, 2004. Available from: URL: http://www.avonex.com

  94. Vedolizumab (Entyvio) package insert. Cambridge: Takeda, 2014. Available from: URL: http://www.general.takedapharm.com

  95. Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Virginia Commonwealth University and McGuire VA Medical Center, GI / Hepatology Service (111-N)1201 Broad Rock Boulevard Richmond, Richmond, VA, 23249, USA

    Jill K. J. Gaidos MD

  2. Mayo Clinic, 200 First St. SW Rochester, Rochester, MN, 55905, USA

    Sunanda V. Kane MD MSPH

Authors
  1. Jill K. J. Gaidos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunanda V. Kane MD MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunanda V. Kane MD MSPH.

Ethics declarations

Conflict of Interest

Jill K. J. Gaidos declares that she has no potential conflict of interest.

Sunanda V. Kane reports research funding from UCB and consulting fees from AbbVie.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Inflammatory Bowel Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaidos, J.K.J., Kane, S.V. Managing IBD Therapies in Pregnancy. Curr Treat Options Gastro 15, 71–83 (2017). https://doi.org/10.1007/s11938-017-0123-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-017-0123-5

Keywords

Search

Navigation